Purchase Solution

Change at Pfizer: Jeff Kindler rhe Wyeth Acquisition

Not what you're looking for?

Ask Custom Question

Discuss the change at Pfizer that Jeff Kindler implemented with the acquisition of Wyeth. Topics should address: what are the issues of the case of the Wyeth Acquisition, cover the pros and cons of the acquisition of Wyeth, A current environmental scan of the company, and internal analysis, How is Pfizer positioned for the future. Common Financial Ratios for Pfizer after the Wyeth Acquisition such as ROE, ROI, Current Ratio, Profit Margin, High Turnover rate, stocks ratio, any important factors to invest or not invest in Pfizer currently.

Purchase this Solution
Solution Summary

This solution discusses the change at Pfizer that Jeff Kindler implemented with the acquisition of Wyeth.

Solution Preview

Please see attached for proper formatting.

Pfizer's acquisition of Wyeth
In January 2009, Pfizer announced acquisition of Wyeth which was valued at $68 billion. The acquisition was completed on October 15, 2009. The combined company created one of the most diversified companies in the global health care industry. The combined company had product offerings in numerous growing therapeutic areas, a strong product pipeline, leading scientific and manufacturing capabilities and a premier global player in the medical industry. Pfizer and Wyeth are complementary businesses and together they can become the best healthcare company in the industry. Together, both companies would be able to achieve much more than any of them would have achieved independently.
The pros of this acquisition are:
Broad and diversified portfolio: Through the acquisition, Pfizer would be able to offer a broad and diversified portfolio of biopharmaceutical innovations through different business units.
New research capabilities: The new combination opens a new pipeline of biopharmaceutical research including programs in diabetes, inflammation, oncology and pain as well as significant opportunities in Wyeth's Alzheimer's disease pipeline.
Enhanced ability to innovate: The new company would have focused business units each tailored to different patient requirements. Each business unit would be responsible to drive product development from clinical trials to commercialization. This approach would allow for rapid decision making and more efficient use of resources which would enhance company's ability to invest in long term opportunities.
Improved manufacturing capabilities: Wyeth has largest integrated biotechnology manufacturing facility in ...

Purchase this Solution
Free BrainMass Quizzes
Paradigms and Frameworks of Management Research

This quiz evaluates your understanding of the paradigm-based and epistimological frameworks of research. It is intended for advanced students.

Operations Management

This quiz tests a student's knowledge about Operations Management

Six Sigma for Process Improvement

A high level understanding of Six Sigma and what it is all about. This just gives you a glimpse of Six Sigma which entails more in-depth knowledge of processes and techniques.

Team Development Strategies

This quiz will assess your knowledge of team-building processes, learning styles, and leadership methods. Team development is essential to creating and maintaining high performing teams.

Employee Orientation

Test your knowledge of employee orientation with this fun and informative quiz. This quiz is meant for beginner and advanced students as well as professionals already working in the HR field.

View More Free Quizzes
Related BrainMass Solutions

  • the negotiation process

    The acquisition of Wyeth will enable Pfizer to diversify into vaccines and inject-able biologic medicine. Wyeth can stress that Pfizer has no other way of replacing its drugs that are scheduled to go generic except through large acquisitions.

  • Product Liability Lawsuit

    In the year 2009, Pfizer purchased Wyeth at the cost of $68 billion. This was a corporate acquisition. Pfizer got access to a large number of Wyeth brands such as Premann, Effexor, and Enbrel.

  • Wyeth Pharmaceuticals: applying technology

    Where possible, Wyeth puts up a pharmaceutical factory on location at a national level so as to make the medicines produced more affordable & of relevance to the local populace.

  • VISA/MASTERCARD

    The reason why I have listed Wyeth as the third choice is that it is a part of Pfizer!

  • Acquisitions

    First, the acquisition of Wyeth by Pfizer in 2009 is unsuccessful The reason is the high cost of acquisition, including a $22.5 billion loan and the decision of Wyeth management team to leave the company after acquisition.

  • Integration of Health Systems

    Further, Pfizer achieves higher market power because of the acquisitions, higher market share, and lower research & development costs. There are instances when acquisition attempts by Pfizer have failed.

  • Weyth, Drug Manufacturer

    In spite of the thrust of Wyeth to increase its R&D there are no strong products in the pipeline that may buttress the sales of Wyeth. Moreover, as described above the acquisition activities of the company have not been successful.

  • Pfizer's combined company's capital structure

    Pfizer won by upping the ante, offering 2.75 shares of its stock for each Warner-Lambert share, a deal valuing Warner-Lambert at $100.89 a share."

  • Amazon's intrapreneurial activity

    The e-tailer needs to make its hardware better, too By Douglas MacMillan Editor's Note: This story has been corrected to change the word iPhone to iPod in the 10th paragraph.

View More Related Solutions